InMed Pharmaceuticals financials
$1.38+1.10%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q4 '26 Jun 30 | Q3 '26 Mar 31 | Q2 '26 Dec 31 | Q1 '26 Sep 30 | Q4 '25 Jun 30 | Q3 '25 Mar 31 | Q2 '25 Dec 31 | Q1 '25 Sep 30 | Q4 '24 Jun 30 | Q3 '24 Mar 31 | Q2 '24 Dec 31 | Q1 '24 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $820.2K | $1.1M | $0.00 | $0.00 | $1.1M | $1.3M | $1.3M | $1.2M | $1.2M | $901.9K |
| Gross profit | $0.00 | $0.00 | $184.2K | $403.2K | $0.00 | $0.00 | $460.9K | $493.4K | $466.1K | $289.5K | $324.1K | $21.2K |
| Gross margin | — | — | 22.5% | 36.0% | — | — | 41.5% | 39.0% | 36.3% | 24.7% | 26.1% | 2.4% |
| Operating income | -$3.2M | -$2.8M | -$2.1M | -$1.8M | -$1.9M | -$2.1M | -$2.2M | -$1.8M | -$2.1M | -$1.8M | -$1.7M | -$2.6M |
| Net income | -$6.3M | -$3.0M | -$2.0M | -$1.7M | -$1.8M | -$2.1M | -$2.6M | -$1.7M | -$1.9M | -$1.7M | -$1.5M | -$2.5M |
| Net margin | — | — | −247.3% | −154.2% | — | — | −231.6% | −132.7% | −151.0% | −146.9% | −119.2% | −281.3% |
| Diluted EPS | $-1.34 | $-0.73 | $-0.51 | $-0.44 | $-1.21 | $-1.94 | $-3.64 | $-2.71 | $-4.05 | $-3.58 | $-3.71 | $-304.80 |
| EBITDA | -$3.2M | -$2.8M | -$2.1M | -$1.7M | -$1.8M | -$2.0M | -$2.2M | -$1.7M | -$2.0M | -$1.7M | -$1.6M | -$2.6M |
| Operating cash flow | -$3.0M | -$1.7M | -$2.4M | -$1.6M | -$2.1M | -$1.7M | -$2.5M | -$1.8M | -$1.0M | -$1.9M | -$1.8M | -$2.2M |
| Free cash flow | -$3.0M | -$1.7M | -$2.4M | -$1.6M | -$2.1M | -$1.7M | -$2.5M | -$1.8M | -$1.0M | -$1.9M | -$1.9M | -$2.2M |
| Diluted shares | 4.7M | 4.0M | 4.0M | 4.0M | 1.5M | 1.1M | 0.7M | 0.6M | 0.5M | 0.5M | 0.4M | 0.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $2.2M | $5.2M | $7.0M | $9.3M | $10.7M | $4.7M |
| Short-term investments | $39.7K | $41.6K | $42.7K | $42.9K | $43.4K | $40.6K |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $3.0M | $9.1M | $11.2M | $13.4M | $15.6M | $9.3M |
| Total liabilities | $2.0M | $2.2M | $1.6M | $1.8M | $2.1M | $2.3M |
| Shareholders' equity | $1.1M | $6.9M | $9.6M | $11.6M | $13.4M | $7.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology